Single User License
INR 129300
Site License
INR 258600
Corporate User License
INR 387900

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Systemic Lupus Erythematosus-Pipeline Review, H1 2015

Systemic Lupus Erythematosus-Pipeline Review, H1 2015


  • Products Id :- GMDHC6687IDB
  • |
  • Pages: 307
  • |
  • June 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Systemic Lupus Erythematosus-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Systemic Lupus Erythematosus-Pipeline Review, H1 2015', provides an overview of the Systemic Lupus Erythematosus's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Systemic Lupus Erythematosus and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Systemic Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Systemic Lupus Erythematosus pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Systemic Lupus Erythematosus Overview 11

Therapeutics Development 12

Pipeline Products for Systemic Lupus Erythematosus-Overview 12

Pipeline Products for Systemic Lupus Erythematosus-Comparative Analysis 13

Systemic Lupus Erythematosus-Therapeutics under Development by Companies 14

Systemic Lupus Erythematosus-Therapeutics under Investigation by Universities/Institutes 19

Systemic Lupus Erythematosus-Pipeline Products Glance 20

Late Stage Products 20

Clinical Stage Products 21

Early Stage Products 22

Unknown Stage Products 23

Systemic Lupus Erythematosus-Products under Development by Companies 24

Systemic Lupus Erythematosus-Products under Investigation by Universities/Institutes 29

Systemic Lupus Erythematosus-Companies Involved in Therapeutics Development 30

4SC AG 30

AbbVie Inc. 31

Ablynx NV 32

Actelion Ltd 33

AiCuris GmbH & Co. KG 34

Amgen Inc. 35

Anthera Pharmaceuticals Inc. 36

Argos Therapeutics, Inc. 37

Biogen, Inc. 38

Biotest AG 39

Bristol-Myers Squibb Company 40

Celgene Corporation 41

Cellular Biomedicine Group, Inc. 42

Eisai Co., Ltd. 43

F. Hoffmann-La Roche Ltd. 44

Genosco 45

Genovax S.r.l. 46

GlaxoSmithKline Plc 47

Hansa Medical AB 48

ImmuNext, Inc. 49

Immunomedics, Inc. 50

Immupharma Plc 51

Invion Limited 52

Johnson & Johnson 53

Kadmon Corporation, LLC 54

Kineta, Inc. 55

Kymab Limited 56

Lead Discovery Center GmbH 57

MacroGenics, Inc. 58

MedAnnex Ltd 59

MedImmune, LLC 60

Medsenic 61

Merck KGaA 62

Mitsubishi Tanabe Pharma Corporation 63

National Pharmaceutical Corp. 64

Neovacs SA 65

Nippon Chemiphar Co., Ltd. 66

Padlock Therapeutics, Inc. 67

Pfizer Inc. 68

Plexxikon Inc. 69

RedHill Biopharma Ltd. 70

Redx Pharma Ltd 71

Resolve Therapeutics, LLC 72

Sanofi 73

Sarepta Therapeutics, Inc. 74

SATT Conectus Alsace SAS 75

SBI Biotech Co., Ltd. 76

Seattle Genetics, Inc. 77

Takeda Pharmaceutical Company Limited 78

Therapix Biosciences Ltd 79

UCB S.A. 80

Xencor, Inc. 81

XTL Biopharmaceuticals Ltd. 82

Systemic Lupus Erythematosus-Therapeutics Assessment 83

Assessment by Monotherapy Products 83

Assessment by Combination Products 84

Assessment by Target 85

Assessment by Mechanism of Action 88

Assessment by Route of Administration 91

Assessment by Molecule Type 93

Drug Profiles 95

(rifabutin + clarithromycin + clofazimine)-Drug Profile 95

abatacept (recombinant)-Drug Profile 98

ABBV-084-Drug Profile 101

ABS-11-Drug Profile 102

AGS-009-Drug Profile 103

AIC-284-Drug Profile 104

ALX-0061-Drug Profile 105

AMG-557-Drug Profile 107

AMG-729-Drug Profile 109

AMG-811-Drug Profile 110

AMP-110-Drug Profile 111

anifrolumab-Drug Profile 113

Annexuzlimab-Drug Profile 114

Antibody to Inhibit ILT7 for Systemic Lupus Erythematosus-Drug Profile 115

Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease-Drug Profile 116

arsenic trioxide-Drug Profile 117

AT-791-Drug Profile 118

atacicept-Drug Profile 119

BB-004-Drug Profile 121

belimumab-Drug Profile 122

BIIB-059-Drug Profile 125

blisibimod-Drug Profile 126

brentuximab vedotin-Drug Profile 129

BT-063-Drug Profile 135

CC-220-Drug Profile 136

Cell Therapy for Autoimmune Diseases and GVHD-Drug Profile 138

dalazatide-Drug Profile 140

dapirolizumab pegol-Drug Profile 142

DCB-3503-Drug Profile 144

Drug to Inhibit PAD for Autoimmune Diseases-Drug Profile 145

E-6446-Drug Profile 147

edratide-Drug Profile 148

Endoglycosidase of Streptococcus pyogenes-Drug Profile 149

epratuzumab-Drug Profile 150

forigerimod acetate-Drug Profile 155

GLB-333-Drug Profile 157

GNKS-356-Drug Profile 158

GX-101-Drug Profile 159

IFNa-Kinoid-Drug Profile 160

IGM-001-Drug Profile 162

IIIM-1-Drug Profile 163

IMP-10-Drug Profile 164

INV-103-Drug Profile 165

KD-025-Drug Profile 167

KY-1015-Drug Profile 168

Leukothera-Drug Profile 169

lulizumab pegol-Drug Profile 171

MGD-010-Drug Profile 172

milatuzumab-Drug Profile 174

Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases-Drug Profile 176

MT-1303-Drug Profile 178

NC-2400-Drug Profile 179

NCS-613-Drug Profile 180

PF-04236921-Drug Profile 181

Recombinant Proteins for Systemic Lupus Erythematosus-Drug Profile 182

RN-486-Drug Profile 183

RO-5461111-Drug Profile 184

RSLV-132-Drug Profile 185

RSLV-133-Drug Profile 186

SAR-113244-Drug Profile 187

SBI-3150-Drug Profile 188

sifalimumab-Drug Profile 189

SM-101-Drug Profile 191

SM-934-Drug Profile 194

Small Molecule to Agonize S1P1 Receptor for Systemic Lupus Erythematosus-Drug Profile 195

Small Molecule to Inhibit BTK for Cancer and Autoimmune disorders-Drug Profile 196

Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology-Drug Profile 197

Small Molecule to Inhibit RORgammat for CNS, Autoimmune and Gastrointestinal Disorders-Drug Profile 199

Small Molecule to Inhibit SYK for Systemic Lupus Erythematosus and Rheumatoid Arthritis-Drug Profile 200

Small Molecules for Systemic Lupus Erythematosus and Rhumatoid Arthritis-Drug Profile 201

Small Molecules to Inhibit FMS Kinase for Immunology, Gastrointestinal, Respiratory and Central Nervous Sytem Diseases-Drug Profile 202

Small Molecules to Inhibit NET Formation for Sepsis and SLE-Drug Profile 203

Stem Cell Therapy for Cerebral Palsy and Systemic Lupus Erythematosus-Drug Profile 204

Stem Cell Therapy for Systemic Lupus Erythematosus-Drug Profile 205

Synthetic Peptide for Systemic Lupus Erythematosus-Drug Profile 206

Synthetic Peptides for Systemic Lupus Erythematosus-Drug Profile 207

TAK-079-Drug Profile 208

TAK-114-Drug Profile 209

TAM-01-Drug Profile 211

ustekinumab-Drug Profile 212

Vaccine for Systemic Lupus Erythematosus-Drug Profile 215

venetoclax-Drug Profile 216

VISTA-Ig-Drug Profile 219

XmAb-5871-Drug Profile 220

Y-27-Drug Profile 221

Systemic Lupus Erythematosus-Recent Pipeline Updates 222

Systemic Lupus Erythematosus-Dormant Projects 282

Systemic Lupus Erythematosus-Discontinued Products 287

Systemic Lupus Erythematosus-Product Development Milestones 289

Featured News & Press Releases 289

Appendix 300

Methodology 300

Coverage 300

Secondary Research 300

Primary Research 300

Expert Panel Validation 300

Contact Us 300

Disclaimer 301

List of Tables

Number of Products under Development for Systemic Lupus Erythematosus, H1 2015 18

Number of Products under Development for Systemic Lupus Erythematosus-Comparative Analysis, H1 2015 19

Number of Products under Development by Companies, H1 2015 21

Number of Products under Development by Companies, H1 2015 (Contd..1) 22

Number of Products under Development by Companies, H1 2015 (Contd..2) 23

Number of Products under Development by Companies, H1 2015 (Contd..3) 24

Number of Products under Investigation by Universities/Institutes, H1 2015 25

Comparative Analysis by Late Stage Development, H1 2015 26

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Development, H1 2015 28

Comparative Analysis by Unknown Stage Development, H1 2015 29

Products under Development by Companies, H1 2015 30

Products under Development by Companies, H1 2015 (Contd..1) 31

Products under Development by Companies, H1 2015 (Contd..2) 32

Products under Development by Companies, H1 2015 (Contd..3) 33

Products under Development by Companies, H1 2015 (Contd..4) 34

Products under Investigation by Universities/Institutes, H1 2015 35

Systemic Lupus Erythematosus-Pipeline by 4SC AG, H1 2015 36

Systemic Lupus Erythematosus-Pipeline by AbbVie Inc., H1 2015 37

Systemic Lupus Erythematosus-Pipeline by Ablynx NV, H1 2015 38

Systemic Lupus Erythematosus-Pipeline by Actelion Ltd, H1 2015 39

Systemic Lupus Erythematosus-Pipeline by AiCuris GmbH & Co. KG, H1 2015 40

Systemic Lupus Erythematosus-Pipeline by Amgen Inc., H1 2015 41

Systemic Lupus Erythematosus-Pipeline by Anthera Pharmaceuticals Inc., H1 2015 42

Systemic Lupus Erythematosus-Pipeline by Argos Therapeutics, Inc., H1 2015 43

Systemic Lupus Erythematosus-Pipeline by Biogen, Inc., H1 2015 44

Systemic Lupus Erythematosus-Pipeline by Biotest AG, H1 2015 45

Systemic Lupus Erythematosus-Pipeline by Bristol-Myers Squibb Company, H1 2015 46

Systemic Lupus Erythematosus-Pipeline by Celgene Corporation, H1 2015 47

Systemic Lupus Erythematosus-Pipeline by Cellular Biomedicine Group, Inc., H1 2015 48

Systemic Lupus Erythematosus-Pipeline by Eisai Co., Ltd., H1 2015 49

Systemic Lupus Erythematosus-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 50

Systemic Lupus Erythematosus-Pipeline by Genosco, H1 2015 51

Systemic Lupus Erythematosus-Pipeline by Genovax S.r.l., H1 2015 52

Systemic Lupus Erythematosus-Pipeline by GlaxoSmithKline Plc, H1 2015 53

Systemic Lupus Erythematosus-Pipeline by Hansa Medical AB, H1 2015 54

Systemic Lupus Erythematosus-Pipeline by ImmuNext, Inc., H1 2015 55

Systemic Lupus Erythematosus-Pipeline by Immunomedics, Inc., H1 2015 56

Systemic Lupus Erythematosus-Pipeline by Immupharma Plc, H1 2015 57

Systemic Lupus Erythematosus-Pipeline by Invion Limited, H1 2015 58

Systemic Lupus Erythematosus-Pipeline by Johnson & Johnson, H1 2015 59

Systemic Lupus Erythematosus-Pipeline by Kadmon Corporation, LLC, H1 2015 60

Systemic Lupus Erythematosus-Pipeline by Kineta, Inc., H1 2015 61

Systemic Lupus Erythematosus-Pipeline by Kymab Limited, H1 2015 62

Systemic Lupus Erythematosus-Pipeline by Lead Discovery Center GmbH, H1 2015 63

Systemic Lupus Erythematosus-Pipeline by MacroGenics, Inc., H1 2015 64

Systemic Lupus Erythematosus-Pipeline by MedAnnex Ltd, H1 2015 65

Systemic Lupus Erythematosus-Pipeline by MedImmune, LLC, H1 2015 66

Systemic Lupus Erythematosus-Pipeline by Medsenic, H1 2015 67

Systemic Lupus Erythematosus-Pipeline by Merck KGaA, H1 2015 68

Systemic Lupus Erythematosus-Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 69

Systemic Lupus Erythematosus-Pipeline by National Pharmaceutical Corp., H1 2015 70

Systemic Lupus Erythematosus-Pipeline by Neovacs SA, H1 2015 71

Systemic Lupus Erythematosus-Pipeline by Nippon Chemiphar Co., Ltd., H1 2015 72

Systemic Lupus Erythematosus-Pipeline by Padlock Therapeutics, Inc., H1 2015 73

Systemic Lupus Erythematosus-Pipeline by Pfizer Inc., H1 2015 74

Systemic Lupus Erythematosus-Pipeline by Plexxikon Inc., H1 2015 75

Systemic Lupus Erythematosus-Pipeline by RedHill Biopharma Ltd., H1 2015 76

Systemic Lupus Erythematosus-Pipeline by Redx Pharma Ltd, H1 2015 77

Systemic Lupus Erythematosus-Pipeline by Resolve Therapeutics, LLC, H1 2015 78

Systemic Lupus Erythematosus-Pipeline by Sanofi, H1 2015 79

Systemic Lupus Erythematosus-Pipeline by Sarepta Therapeutics, Inc., H1 2015 80

Systemic Lupus Erythematosus-Pipeline by SATT Conectus Alsace SAS, H1 2015 81

Systemic Lupus Erythematosus-Pipeline by SBI Biotech Co., Ltd., H1 2015 82

Systemic Lupus Erythematosus-Pipeline by Seattle Genetics, Inc., H1 2015 83

Systemic Lupus Erythematosus-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 84

Systemic Lupus Erythematosus-Pipeline by Therapix Biosciences Ltd, H1 2015 85

Systemic Lupus Erythematosus-Pipeline by UCB S.A., H1 2015 86

Systemic Lupus Erythematosus-Pipeline by Xencor, Inc., H1 2015 87

Systemic Lupus Erythematosus-Pipeline by XTL Biopharmaceuticals Ltd., H1 2015 88

Assessment by Monotherapy Products, H1 2015 89

Assessment by Combination Products, H1 2015 90

Number of Products by Stage and Target, H1 2015 92

Number of Products by Stage and Mechanism of Action, H1 2015 95

Number of Products by Stage and Route of Administration, H1 2015 98

Number of Products by Stage and Molecule Type, H1 2015 100

Systemic Lupus Erythematosus Therapeutics-Recent Pipeline Updates, H1 2015 228

Systemic Lupus Erythematosus-Dormant Projects, H1 2015 288

Systemic Lupus Erythematosus-Dormant Projects (Contd..1), H1 2015 289

Systemic Lupus Erythematosus-Dormant Projects (Contd..2), H1 2015 290

Systemic Lupus Erythematosus-Dormant Projects (Contd..3), H1 2015 291

Systemic Lupus Erythematosus-Dormant Projects (Contd..4), H1 2015 292

Systemic Lupus Erythematosus-Discontinued Products, H1 2015 293

Systemic Lupus Erythematosus-Discontinued Products (Contd..1), H1 2015 294

List of Figures

Number of Products under Development for Systemic Lupus Erythematosus, H1 2015 18

Number of Products under Development for Systemic Lupus Erythematosus-Comparative Analysis, H1 2015 19

Number of Products under Development by Companies, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 27

Comparative Analysis by Early Stage Products, H1 2015 28

Assessment by Monotherapy Products, H1 2015 89

Number of Products by Top 10 Targets, H1 2015 91

Number of Products by Stage and Top 10 Targets, H1 2015 91

Number of Products by Top 10 Mechanism of Actions, H1 2015 94

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 94

Number of Products by Top 10 Routes of Administration, H1 2015 97

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 97

Number of Products by Top 10 Molecule Types, H1 2015 99

Number of Products by Stage and Top 10 Molecule Types, H1 2015 99

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AbbVie Inc.

Ablynx NV

Actelion Ltd

AiCuris GmbH & Co. KG

Amgen Inc.

Anthera Pharmaceuticals Inc.

Argos Therapeutics, Inc.

Biogen, Inc.

Biotest AG

Bristol-Myers Squibb Company

Celgene Corporation

Cellular Biomedicine Group, Inc.

Eisai Co., Ltd.

F. Hoffmann-La Roche Ltd.

Genosco

Genovax S.r.l.

GlaxoSmithKline Plc

Hansa Medical AB

ImmuNext, Inc.

Immunomedics, Inc.

Immupharma Plc

Invion Limited

Johnson & Johnson

Kadmon Corporation, LLC

Kineta, Inc.

Kymab Limited

Lead Discovery Center GmbH

MacroGenics, Inc.

MedAnnex Ltd

MedImmune, LLC

Medsenic

Merck KGaA

Mitsubishi Tanabe Pharma Corporation

National Pharmaceutical Corp.

Neovacs SA

Nippon Chemiphar Co., Ltd.

Padlock Therapeutics, Inc.

Pfizer Inc.

Plexxikon Inc.

RedHill Biopharma Ltd.

Redx Pharma Ltd

Resolve Therapeutics, LLC

Sanofi

Sarepta Therapeutics, Inc.

SATT Conectus Alsace SAS

SBI Biotech Co., Ltd.

Seattle Genetics, Inc.

Takeda Pharmaceutical Company Limited

Therapix Biosciences Ltd

UCB S.A.

Xencor, Inc.

XTL Biopharmaceuticals Ltd.

Systemic Lupus Erythematosus Therapeutic Products under Development, Key Players in Systemic Lupus Erythematosus Therapeutics, Systemic Lupus Erythematosus Pipeline Overview, Systemic Lupus Erythematosus Pipeline, Systemic Lupus Erythematosus Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com